4,5-diphenyl-2-methyl-1,2,3-triazole | 21690-97-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4,5-diphenyl-2-methyl-1,2,3-triazole
• 英文别名: 2-methyl-4,5-diphenyl-2H-1,2,3-triazole；2-Methyl-4,5-diphenyl-1,2,3-triazol；2-Methyl-4,5-diphenyltriazole
• CAS: 21690-97-1
• 化学式: C₁₅H₁₃N₃
• 分子量: 235.288
• InChiKey: CEVKQPBZPVRLSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-(4-methoxyphenyl)-4,5-diphenyl-2H-1,2,3-triazole 在 ammonium cerium (IV) nitrate 、 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 144.0h， 生成 1-methyl-4,5-diphenyl-1H-1,2,3-triazole 、 4,5-diphenyl-2-methyl-1,2,3-triazole
  参考文献：
  名称：

  铜与芳基重氮盐催化的铜环化法合成三碳取代的N2-芳基-1,2,3-三唑

  摘要：

  迄今为止，与N 1-芳基对应物相比，完全取代的N 2-芳基-1,2,3-三唑的一般合成具有挑战性。在本文中，我们描述了铜催化的叠氮化物和芳基重氮盐的环化反应。该区域特异性方法允许获得广泛的被各种芳基和烷基部分取代的三碳N 2-芳基-1,2,3-三唑的光谱。几种适用于药物发现的三唑前体的合成，以及带有三唑部分的新型手性联萘配体，突出了其实用性。

  DOI：

  10.1021/acs.joc.0c01433

文献信息

• A Ceric Ammonium Nitrate N-Dearylation of <i>N</i>-<i>p</i>-Anisylazoles Applied to Pyrazole, Triazole, Tetrazole, and Pentazole Rings:  Release of Parent Azoles. Generation of Unstable Pentazole, HN₅/N₅^-, in Solution
  作者：Richard N. Butler、John M. Hanniffy、John C. Stephens、Luke A. Burke

  DOI：10.1021/jo702423z

  日期：2008.2.1

  pentazole ring. The unstable HN5/N5- produced at −40 °C did not build up in the solution but degraded to azide ion and nitrogen gas with a short lifetime. The 15N-labeling of the N3- ion obtained from all samples proved unequivocally that it came from the degradation of HN5 (tautomeric forms) and/or its anion N5- in the solution.

  硝酸铈（IV）铵铵（CAN）与一系列N-（对-茴香基）唑在乙腈或甲醇溶剂中的反应导致N-脱芳基反应以可比的产率释放母体NH-唑和对-苯醌。探索了反应的范围和局限性。它与1-（对-茴香基）吡唑，2-（对-茴香基）-1,2,3-三唑，2-（对-茴香基）-2 H-四唑和1-（对-茴香基）成功戊唑 脱芳基使对-茴香基基团成为在唑化学中潜在有用的N-保护基团。1-（对-茴香基）戊唑在溶液中释放的唑是不稳定的HN5，盼望已久的母体戊唑酸。对戊基戊唑样品是通过在戊唑环的所有位置上分别具有一个，两个和三个15 N原子的组合而合成的。不稳定的HN 5 / N 5 -在-40产生℃下未建立在溶液中，但降解成叠氮化物离子和氮气具有短的寿命。的15的N N-二标记3 -从所有样品得到的离子明确证明，它来自HN的降解5（互变异构形式）和/或它的阴离子ñ 5 -在溶液中。
• TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20080038225A1

  公开（公告）日：2008-02-14

  The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.

  本发明涉及以下式I或II的化合物，或其药用盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰乙型肝炎病毒的生命周期，同时也可作为抗病毒剂使用。本发明还涉及包含上述化合物的药物组合物，用于治疗HCV感染的患者。该发明还涉及通过向患者施用包含本发明化合物的药物组合物来治疗患者的HCV感染的方法。
• TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20090047248A1

  公开（公告）日：2009-02-19

  The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.

  本发明涉及公式I或II的化合物，或其药学上可接受的盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰乙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包含上述化合物的制剂，用于治疗患有HCV感染的受试者。本发明还涉及通过向受试者给予本发明化合物的制剂来治疗受试者的HCV感染的方法。
• GILCHRIST T. L.; GYMER G. E.; REES C. W., J. CHEM. SOC. PERKIN TRANS. <JCPK-BH>, 1975, PART 1, NO 1, 1-8
  作者：GILCHRIST T. L.、 GYMER G. E.、 REES C. W.

  DOI：——

  日期：——
• 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Phadke Avinash

  公开号：US20100216725A1

  公开（公告）日：2010-08-26

  The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R 1 , R 6 -R 8 , R 16 , R 18 , R 19 , M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.